Ajooni Biotech (AJOONI)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades below book value with P/B of 0.79, providing an asset cushion
• Low leverage: Debt/Equity of only 0.11
• Strong recent growth: Sales up 72.64% and profit up 126.03%
• Piotroski F-Score of 7/9 suggests improving fundamentals
• Latest quarter momentum: Sales ₹59 Cr and Net Profit ₹2 Cr

Concerns

• Low profitability: ROE of 5.51% and ROCE of 6.91%
• Thin net margins around 3.4% in a commodity animal feed business
• Promoter holding is only 26.89%, limiting owner alignment
• No dividend, so minority return depends entirely on growth execution

AI Analysis

At ₹4.36, Ajooni’s market cap of ₹76 Cr is not much above my threshold for a meaningful position. It sells below book value — ₹5.53 per share — so on a Graham basis the asset cushion is there, and debt/equity of 0.11 is comfortable. The Piotroski F-Score of 7/9 points to improving fundamentals. But I never buy a business solely because it is cheap; the price must be justified by the long-term return on capital. Here ROE is just 5.51% and ROCE is 6.91%. That tells me management is not earning a superior return on what shareholders have entrusted to them. The latest quarter shows sales of ₹59 Cr and net profit of ₹2 Cr — a net margin around 3.4%. In animal feed, a commodity input business, such margins can evaporate quickly as raw material prices move or dairy economics turn against farmers. Sales growth of 72.64% and profit growth of 126.03% sound wonderful, but they start from a low base. The PEG ratio of 0.16 is a statistical illusion unless growth is durable and profitable. I also see promoter holding of only 26.89%; I want owners to have their wealth aligned with mine. There is no dividend, so minority shareholders rely entirely on earnings reinvestment and eventual price realisation. If the company can convert these high growth rates into consistently higher ROE and maintain its low debt, the current discount to book could be an opportunity. Until then, I would call it a small speculative fast grower, not a core holding. I'll keep it on the watch list and demand evidence of a durable moat.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer